NEA Management Company, LLC reported 25 holdings worth US$1.36B as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
NEA Management Company, LLC reported 25 holdings worth US$1.36B as of Sep 30, 2026. Largest: MBX Biosciences, Inc., SpyGlass Pharma, Inc. and Trevi Therapeutics, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 25
- Value as reported
- US$1.36B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| MBX Biosciences, Inc. | 3.61M | US$212M | 15.5% |
| SpyGlass Pharma, Inc. | 7.39M | US$192M | 14.1% |
| Trevi Therapeutics, Inc. | 13.2M | US$189M | 13.9% |
| Celcuity Inc. | 1.71M | US$136M | 10.0% |
| Savara, Inc. | 24.5M | US$126M | 9.3% |
| Zenas BioPharma, Inc. | 4.02M | US$109M | 8.0% |
| Monte Rosa Therapeutics, Inc. | 6.69M | US$79.8M | 5.9% |
| Aurinia Pharmaceuticals Inc | 3.97M | US$64.3M | 4.7% |
| Coursera, Inc. | 12.9M | US$63.8M | 4.7% |
| ORIC Pharmaceuticals, Inc. | 4.12M | US$55.5M | 4.1% |
| Phathom Pharmaceuticals, Inc. | 1.96M | US$14.3M | 1.0% |
| Korro Bio, Inc. | 1.3M | US$12.9M | 0.94% |
| Nkarta, Inc. | 3.57M | US$9.35M | 0.69% |
| Champions Oncology, Inc. | 1.71M | US$8.57M | 0.63% |
| Black Diamond Therapeutics, Inc. | 4.45M | US$8.39M | 0.61% |
| Inventiva SA | 1.46M | US$5.4M | 0.40% |
| CVRx, Inc. | 1.95M | US$3.42M | 0.25% |
| Marker Therapeutics, Inc. | 1.63M | US$1.74M | 0.13% |
| LeonaBio, Inc. | 464K | US$1.66M | 0.12% |
| OnKure Therapeutics, Inc. | 479K | US$1.3M | 0.10% |
| ImageneBio, Inc. | 50,005 | US$229K | 0.02% |
| Gossamer Bio, Inc. | 12,500 | US$148K | 0.01% |
| Karyopharm Therapeutics Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC